24/7 Market News- Sangamo Therapeutics Expounds on Pfizer’s Positive Topline Phase 3 Hemophilia A Gene Therapy Candidate Trial Results

July 24, 2024

DENVER, Colo., Jul 24, 2024 (247marketnews.com)- Sangamo Therapeutics, Inc. (Nasdaq:SGMO) expounded on Pfizer’s (NYSE:PFE) positive topline results from their Phase 3 AFFINE trial (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy that Sangamo is co-developing with and licensing to Pfizer for the treatment of adults with moderately severe to severe hemophilia A, for which Sangamo is eligible to earn up to $220 million in milestone payments from Pfizer.

Pfizer reported that the AFFINE trial achieved primary and key secondary objectives of superiority compared to prophylaxis.

Professor Andrew Leavitt M.D., the AFFINE lead investigator, said, “For people living with hemophilia A, the physical and emotional impact of needing to prevent and treat bleeding episodes through frequent IV infusions or injections cannot be underestimated.

“I’m excited by the strength of these positive results from the AFFINE trial that show giroctocogene fitelparvovec was generally well tolerated, and demonstrate the transformative potential of this gene therapy candidate to provide superior bleed protection compared with routine FVIII prophylaxis, while helping relieve the treatment burden for people living with hemophilia A.”

Pfizer reported that the AFFINE trial achieved primary and key secondary objectives of superiority compared to prophylaxis.

Nathalie Dubois-Stringfellow, Ph.D, Sangamo’s Chief Development Officer, commented, “We are thrilled with the positive topline results from the Phase 3 AFFINE trial, which demonstrated the potential of giroctocogene fitelparvovec as a one-time gene therapy for people with hemophilia A and provide a potential alternative to the current burden of disease management.

“These impressive results further validate the power of our genomic technologies and take us one step closer towards what could become Sangamo’s first medicine commercially available to patients. We greatly appreciate Pfizer’s strong leadership of this important program and look forward to their discussions of these data with regulatory authorities.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SGMO, PFE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.